OSPOLOT

This brand name is authorized in Australia, Austria, Estonia, Israel, Japan, Lithuania.

Active ingredients

The drug OSPOLOT contains one active pharmaceutical ingredient (API):

1
UNII I00Q766CZ2 - SULTHIAME
 

Sultiame is indicated as an anticonvulsant for behavioural disorders associated with epilepsy; hyperkinetic behaviour; temporal lobe epilepsy; myoclonic seizures; grand mal attacks; Jacksonian seizures.
 
Read more about Sultiame

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
N03AX03 Sultiame N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AX Other antiepileptics
Discover more medicines within N03AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 2099L, 2100M
EE Ravimiamet 1423909
IL מִשְׂרַד הַבְּרִיאוּת 2977
JP 医薬品医療機器総合機構 1137001F1039, 1137001F2035
LT Valstybinė vaistų kontrolės tarnyba 1004589, 1068692, 1091728

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈